Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study
Authors:
Open Access
Abstract
Objectives To investigate the association between contemporary combined hormonal contraceptives (including progestogen types in combined preparations and all progestogen-only products) and overall and specific types of ovarian cancer. Design Prospective, nationwide cohort study. Setting Denmark, 1995-2014. Participants All women aged 15-49 years during 1995-2014 were eligible. Women were excluded if they immigrated after 1995, had cancer (except non-melanoma skin cancer), had venous thrombosis, or were treated for infertility before entry (final study population included 1 879 227 women). Women were categorised as never users (no record of being dispensed hormonal contraception), current or recent users (≤1 year after stopping use), or former users (>1 year after stopping use) of different hormonal contraceptives. Main outcome measures Poisson regression was used to calculate relative risk of ovarian cancer among users of any contemporary combined hormonal contraceptives and by progestogen type in combined preparations and all progestogen-only products, including non-oral preparations. Separate analyses examined women followed up to their first contraception type switch and those with full contraceptive histories. Duration, time since last use, and tumour histology were examined and the population prevented fraction were calculated. Results During 21.4 million person years, 1249 incident ovarian cancers occurred. Among ever users of hormonal contraception, 478 ovarian cancers were recorded over 13 344 531 person years. Never users had 771 ovarian cancers during 8 150 250 person years. Compared with never users, reduced risks of ovarian cancer occurred with current or recent use and former use of any hormonal contraception (relative risk 0.58 (95% confidence interval 0.49 to 0.68) and 0.77 (0.66 to 0.91), respectively). Relative risks among current or recent users decreased with increasing duration (from 0.82 (0.59 to 1.12) with ≤1 year use to 0.26 (0.16 to 0.43) with >10 years’ use; PConclusions Use of contemporary combined hormonal contraceptives is associated with a reduction in ovarian cancer risk in women of reproductive age—an effect related to duration of use, which diminishes after stopping use. These data suggest no protective effect from progestogen-only products.Keywords
This publication has 27 references indexed in Scilit:
- Oral contraceptive use and cancer: final report from the Oxford–Family Planning Association contraceptive studyContraception, 2013
- Thrombotic Stroke and Myocardial Infarction with Hormonal ContraceptionNew England Journal of Medicine, 2012
- Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case–control studyBJOG: An International Journal of Obstetrics & Gynaecology, 2012
- Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control StudyPLOS Medicine, 2012
- Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and NutritionBritish Journal of Cancer, 2011
- Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesisPathology, 2011
- Hormone Therapy and Ovarian CancerJAMA, 2009
- Using prescription registries to define continuous drug use: how to fill gaps between prescriptionsPharmacoepidemiology and Drug Safety, 2008
- Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controlsThe Lancet, 2008
- Revised FIGO staging for gynaecological cancerBJOG: An International Journal of Obstetrics & Gynaecology, 1989